Adherence to the Canadian Hemoglobinopathy Association neurological screening guidelines for pediatric patients with sickle cell disease in Alberta
Paediatrics & Child Health · 20.08.2026
DOI: 10.1093/pch/pxag073 ↗Kurz gefasst
Leitlinie in der Zeitschrift Paediatrics & Child Health, online erschienen am 20.08.2026. Verfasst von Payton Hooey und 3 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
Objectives
The Canadian Hemoglobinopathy Association (CanHaem) consensus statement recommends (1) annual transcranial Doppler (TCD) imaging for stroke risk in patients ≥2 years old, (2) at least one screening magnetic resonance imaging and angiography (MRI/A) during childhood to assess for silent infarcts, and (3) routine monitoring of school performance and neuropsychological assessments. The purpose of this study was to assess whether the guidelines are adhered to.
Methods
Retrospective chart review assessing how closely the CanHaem neurologic screening recommendations are being followed at the two major Alberta pediatric centers and characterized the frequency of neuroimaging abnormalities and cognitive and developmental diagnoses in our population.
Results
The study included 316 patients; 74% homozygous S (HbSS). Annual TCD screening of children ≥2 years old with HbSS or homozygous S beta-null thalassemia (HbSB 0 ) genotypes was 62% over 2 years. Most patients demonstrated normal velocities; 7.3% had conditional velocities (170 to 199 cm/s), and 2.7% had abnormal velocities (≥200 cm/s). Screening MRI/As were completed in 19% of patients. Silent infarctions, strokes and vasculopathies were identified in 16% of patients with MRI/As. Over 90% of patients were screened for cognitive and developmental concerns during clinic visits, resulting in follow-up neuropsychological assessments (18%) and developmental-pediatric referrals (3%). Identified concerns included academic challenges (11%), cognitive disorders (1.3%), and neurodevelopmental disorders (17%).
Conclusion
Adherence to CanHaem neurological screening recommendations was low, with major gaps in completion of annual TCDs, screening MRI/A, and neuropsychological assessments. To improve screening rates, we need to better understand patient- and system-level factors that act as barriers.
Zitieren
APA
Hooey, P., Corriveau-Bourque, C., Singh, G., & Bruce, A. (2026). Adherence to the Canadian Hemoglobinopathy Association neurological screening guidelines for pediatric patients with sickle cell disease in Alberta. Paediatrics & Child Health. https://doi.org/10.1093/pch/pxag073
Vancouver
Hooey P, Corriveau-Bourque C, Singh G, Bruce A. Adherence to the Canadian Hemoglobinopathy Association neurological screening guidelines for pediatric patients with sickle cell disease in Alberta. Paediatrics & Child Health. 2026. doi:10.1093/pch/pxag073
BibTeX
@article{Hooey2026,
author = {Hooey, Payton and Corriveau-Bourque, Catherine and Singh, Gurpreet and Bruce, Aisha},
title = {Adherence to the Canadian Hemoglobinopathy Association neurological screening guidelines for pediatric patients with sickle cell disease in Alberta},
journal = {Paediatrics & Child Health},
year = {2026},
doi = {10.1093/pch/pxag073}
}
EUVIMED